INBRX-121 / Inhibrx Biosci - LARVOL DELTA

INBRX-121, a safe and efficacious molecular targeted cytokine that enhances NK cell-mediated tumor killing (AACR 2022) - "Further, many of the toxicities associated with T cell therapeutics have not been observed with NK-centric treatments. INBRX-121 therefore provides a promising safe and efficacious treatment option for a broad array of cancer indications both as a monotherapy and in combination with ADCC-enabled antibodies."

Oncology • FCGR3A • STAT5

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting (PRNewswire) - "Inhibrx...announced today that data from INBRX-121 and INBRX-130 will be presented at the 2022 American Association for Cancer Research ('AACR') Annual Meeting...'We are excited to share some of the updated preclinical data for our targeted cytokine platform and INBRX-121 that specifically expands and enhances the cytotoxic capacity of NK cells. Additionally, we will introduce our unique T-cell engager platform, CONTRA-MAB®, and INBRX-130 that targets the 5T4 antigen on solid tumors'..."

Preclinical • Oncology • Solid Tumor

INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities (SITC 2021) - "Characterization of the pharmacokinetic/pharmacodynamic relationship of INBRX-121 was completed in non-human primates across escalating dose levels, while anti-tumor activity as a monotherapy and in combination with Rituximab or PD-1 checkpoint blockade was tested in Raji xenografts and syngeneic CT-26 mouse models, respectively. NKp46-targeting of a detuned IL-2 variant helps to avoid IL-2-mediated toxicity while enhancing the antitumor activities of NK cells. Through its novel therapeutic concept INBRX-121 provides a promising treatment option for multiple cancer indications both as a monotherapy and in combination with a variety of frontline agents."

Combination therapy • Monotherapy • Oncology • GZMB • IL2 • IL2RA • STAT5 • STAT5AWqe

Inhibrx Announces Presentations at SITC 2021 (PRNewswire) - "Inhibrx, Inc...announced today that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer's (SITC) annual meeting, to be held in Washington, D.C. and in a virtual platform, on November 10-14, 2021....'We are excited to share some of the preclinical data related to our clinical candidates, INBRX-105 and INBRX-106, which inform the selection of pharmacodynamic biomarkers, dosing and clinical strategy,'...'Additionally, we will be introducing the first emerging pipeline candidate from our targeted cytokine platform, INBRX-121, which specifically expands and enhances the cytotoxic capacity of NK cells.'"

Preclinical • Oncology • Solid Tumor